Latest Breaking News On - Fujirebio holdings inc - Page 1 : comparemela.com

Sysmex : Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2024

Neurological Biomarkers Market size is set to grow by USD 7.82 billion from 2024-2028, rising incidence of neurological disorders boost the market, Technavio

/PRNewswire/ The global neurological biomarkers market size is estimated to grow by USD 7.82 bn from 2024-2028, according to Technavio. The market is.

Fujirebio and Agappe Enter into an Agreement on Business Collaboration in the Field of CLIA Based Immunoassay

Fujirebio Holdings Inc. and Agappe Diagnostics Ltd today announced that they have entered into an agreement of Contract Development and Manufacturing Organization CDMO partnership for Cartridge based CLIA system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121.

Fujirebio Expands Its Alzheimers Disease Test Menu With the Much Awaited and Fully Automated Lumipulse G pTau 217 Plasma Assay for Research Use Only RUO

H.U. Group Holdings Inc. and its whollyowned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

Fujirebio Expands Its Alzheimer's Disease Test Menu With the Much Awaited and Fully Automated Lumipulse® G pTau 217 Plasma Assay for Research Use Only (RUO)